STATT

A titrate-to-goal study of Simvastatin in Asian patients with coronary heart disease

Namsik Chung, Seung Yun Cho, Donghoon Choi, Jun Ren Zhu, Kathy Lee, Pui Yin Lee, Sang Hoon Lee, Sahng Lee, Jiann Jong Wang, Wei Hsien Yin, Mason Shing Young, Kwang Kon Koh, Ji Won Son, Somkiat Sangwatanaroj, Pradit Panchavinnin, Rewat Phankingthongkum, Nai Sheng Cai, Wei Fu Fan

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Most published studies on the use of lipid-lowering agents to treat hyper-cholesterolemia have focused on Western populations, with few data on Asian populations. Objective: The Simvastatin Treats Asians to Target (STATT) study used a titrate-to-goal protocol to evaluate the efficacy and tolerability of simvastatin 20 to 80 mg/d in the treatment of Asian patients with coronary heart disease. Methods: This was a multicenter, open-label, uncontrolled, 14-week study in patients with coronary heart disease and serum low-density lipoprotein cholesterol (LDL-C) levels of 115-180 mg/dL and triglyceride levels of ≤400 mg/dL. The dose of simvastatin was titrated from 20 to 80 mg/d to achieve the National Cholesterol Education Program (NCEP) LDL-C target of ≤100 mg/dL. The primary efficacy measure was the percentage of patients achieving the NCEP target. Among secondary measures were the percentage of patients achieving European Society of Cardiology/European Atherosclerosis Society/European Society of Hypertension target LDL-C levels of ≤115 mg/dL and the percentage change from baseline in lipid parameters. Tolerability was assessed in terms of the overall incidence of adverse experiences and the incidences of the most commonly reported adverse experiences. Results: The intent-to-treat analysis included 133 Asian patients (93 men, 40 women; mean age, 59.5 years), of whom 125 completed 14 weeks of therapy. Their mean blood pressure was 130.2/79.4 mm Hg. Overall, 104 (78.2%) patients treated with simvastatin achieved LDL-C levels ≤100 mg/dL at week 14, and 125 (94.0%) achieved this target at some point during the study. Similarly, 122 (91.7%) patients achieved an LDL-C level ≤115 mg/dL at week 14, and 130 (97.7%) achieved this target at some point during the study. Treatment with simvastatin had favorable effects on the lipid profile, producing significant percentage changes from baseline in all parameters (P < 0.001). Simvastatin was well tolerated across the dose range. Overall, 40 patients (30.1%) had ≥1 clinical adverse experience. Only 14 (10.5%) had adverse experiences that were possibly, probably, or definitely related to study drug; none of these experiences were considered serious. The most common adverse experiences (≥3% incidence) were abdominal pain (6%); chest pain (5%); dizziness (4%); and asthenia/fatigue, fibromyalgia, headache, insomnia, and upper respiratory tract infection (3% each). No new or unexpected adverse experiences were seen at the higher doses. Conclusions: Simvastatin was effective and well tolerated at doses of 20, 40, and 80 mg/d in Asian patients with coronary heart disease. Titration enabled the majority to achieve target LDL-C levels of ≤100 mg/dL.

Original languageEnglish
Pages (from-to)858-870
Number of pages13
JournalClinical Therapeutics
Volume23
Issue number6
DOIs
Publication statusPublished - 2001 Jan 1

Fingerprint

Simvastatin
Coronary Disease
LDL Cholesterol
Lipids
Incidence
Cholesterol
Education
Asthenia
Fibromyalgia
Sleep Initiation and Maintenance Disorders
Dizziness
Chest Pain
Respiratory Tract Infections
Abdominal Pain
Population
Fatigue
Headache
Triglycerides
Therapeutics
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Chung, Namsik ; Cho, Seung Yun ; Choi, Donghoon ; Zhu, Jun Ren ; Lee, Kathy ; Lee, Pui Yin ; Lee, Sang Hoon ; Lee, Sahng ; Wang, Jiann Jong ; Yin, Wei Hsien ; Young, Mason Shing ; Koh, Kwang Kon ; Son, Ji Won ; Sangwatanaroj, Somkiat ; Panchavinnin, Pradit ; Phankingthongkum, Rewat ; Cai, Nai Sheng ; Fan, Wei Fu. / STATT : A titrate-to-goal study of Simvastatin in Asian patients with coronary heart disease. In: Clinical Therapeutics. 2001 ; Vol. 23, No. 6. pp. 858-870.
@article{6a6d1f41daab43e0b7985ee06a5609ef,
title = "STATT: A titrate-to-goal study of Simvastatin in Asian patients with coronary heart disease",
abstract = "Background: Most published studies on the use of lipid-lowering agents to treat hyper-cholesterolemia have focused on Western populations, with few data on Asian populations. Objective: The Simvastatin Treats Asians to Target (STATT) study used a titrate-to-goal protocol to evaluate the efficacy and tolerability of simvastatin 20 to 80 mg/d in the treatment of Asian patients with coronary heart disease. Methods: This was a multicenter, open-label, uncontrolled, 14-week study in patients with coronary heart disease and serum low-density lipoprotein cholesterol (LDL-C) levels of 115-180 mg/dL and triglyceride levels of ≤400 mg/dL. The dose of simvastatin was titrated from 20 to 80 mg/d to achieve the National Cholesterol Education Program (NCEP) LDL-C target of ≤100 mg/dL. The primary efficacy measure was the percentage of patients achieving the NCEP target. Among secondary measures were the percentage of patients achieving European Society of Cardiology/European Atherosclerosis Society/European Society of Hypertension target LDL-C levels of ≤115 mg/dL and the percentage change from baseline in lipid parameters. Tolerability was assessed in terms of the overall incidence of adverse experiences and the incidences of the most commonly reported adverse experiences. Results: The intent-to-treat analysis included 133 Asian patients (93 men, 40 women; mean age, 59.5 years), of whom 125 completed 14 weeks of therapy. Their mean blood pressure was 130.2/79.4 mm Hg. Overall, 104 (78.2{\%}) patients treated with simvastatin achieved LDL-C levels ≤100 mg/dL at week 14, and 125 (94.0{\%}) achieved this target at some point during the study. Similarly, 122 (91.7{\%}) patients achieved an LDL-C level ≤115 mg/dL at week 14, and 130 (97.7{\%}) achieved this target at some point during the study. Treatment with simvastatin had favorable effects on the lipid profile, producing significant percentage changes from baseline in all parameters (P < 0.001). Simvastatin was well tolerated across the dose range. Overall, 40 patients (30.1{\%}) had ≥1 clinical adverse experience. Only 14 (10.5{\%}) had adverse experiences that were possibly, probably, or definitely related to study drug; none of these experiences were considered serious. The most common adverse experiences (≥3{\%} incidence) were abdominal pain (6{\%}); chest pain (5{\%}); dizziness (4{\%}); and asthenia/fatigue, fibromyalgia, headache, insomnia, and upper respiratory tract infection (3{\%} each). No new or unexpected adverse experiences were seen at the higher doses. Conclusions: Simvastatin was effective and well tolerated at doses of 20, 40, and 80 mg/d in Asian patients with coronary heart disease. Titration enabled the majority to achieve target LDL-C levels of ≤100 mg/dL.",
author = "Namsik Chung and Cho, {Seung Yun} and Donghoon Choi and Zhu, {Jun Ren} and Kathy Lee and Lee, {Pui Yin} and Lee, {Sang Hoon} and Sahng Lee and Wang, {Jiann Jong} and Yin, {Wei Hsien} and Young, {Mason Shing} and Koh, {Kwang Kon} and Son, {Ji Won} and Somkiat Sangwatanaroj and Pradit Panchavinnin and Rewat Phankingthongkum and Cai, {Nai Sheng} and Fan, {Wei Fu}",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0149-2918(01)80074-6",
language = "English",
volume = "23",
pages = "858--870",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

Chung, N, Cho, SY, Choi, D, Zhu, JR, Lee, K, Lee, PY, Lee, SH, Lee, S, Wang, JJ, Yin, WH, Young, MS, Koh, KK, Son, JW, Sangwatanaroj, S, Panchavinnin, P, Phankingthongkum, R, Cai, NS & Fan, WF 2001, 'STATT: A titrate-to-goal study of Simvastatin in Asian patients with coronary heart disease', Clinical Therapeutics, vol. 23, no. 6, pp. 858-870. https://doi.org/10.1016/S0149-2918(01)80074-6

STATT : A titrate-to-goal study of Simvastatin in Asian patients with coronary heart disease. / Chung, Namsik; Cho, Seung Yun; Choi, Donghoon; Zhu, Jun Ren; Lee, Kathy; Lee, Pui Yin; Lee, Sang Hoon; Lee, Sahng; Wang, Jiann Jong; Yin, Wei Hsien; Young, Mason Shing; Koh, Kwang Kon; Son, Ji Won; Sangwatanaroj, Somkiat; Panchavinnin, Pradit; Phankingthongkum, Rewat; Cai, Nai Sheng; Fan, Wei Fu.

In: Clinical Therapeutics, Vol. 23, No. 6, 01.01.2001, p. 858-870.

Research output: Contribution to journalArticle

TY - JOUR

T1 - STATT

T2 - A titrate-to-goal study of Simvastatin in Asian patients with coronary heart disease

AU - Chung, Namsik

AU - Cho, Seung Yun

AU - Choi, Donghoon

AU - Zhu, Jun Ren

AU - Lee, Kathy

AU - Lee, Pui Yin

AU - Lee, Sang Hoon

AU - Lee, Sahng

AU - Wang, Jiann Jong

AU - Yin, Wei Hsien

AU - Young, Mason Shing

AU - Koh, Kwang Kon

AU - Son, Ji Won

AU - Sangwatanaroj, Somkiat

AU - Panchavinnin, Pradit

AU - Phankingthongkum, Rewat

AU - Cai, Nai Sheng

AU - Fan, Wei Fu

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: Most published studies on the use of lipid-lowering agents to treat hyper-cholesterolemia have focused on Western populations, with few data on Asian populations. Objective: The Simvastatin Treats Asians to Target (STATT) study used a titrate-to-goal protocol to evaluate the efficacy and tolerability of simvastatin 20 to 80 mg/d in the treatment of Asian patients with coronary heart disease. Methods: This was a multicenter, open-label, uncontrolled, 14-week study in patients with coronary heart disease and serum low-density lipoprotein cholesterol (LDL-C) levels of 115-180 mg/dL and triglyceride levels of ≤400 mg/dL. The dose of simvastatin was titrated from 20 to 80 mg/d to achieve the National Cholesterol Education Program (NCEP) LDL-C target of ≤100 mg/dL. The primary efficacy measure was the percentage of patients achieving the NCEP target. Among secondary measures were the percentage of patients achieving European Society of Cardiology/European Atherosclerosis Society/European Society of Hypertension target LDL-C levels of ≤115 mg/dL and the percentage change from baseline in lipid parameters. Tolerability was assessed in terms of the overall incidence of adverse experiences and the incidences of the most commonly reported adverse experiences. Results: The intent-to-treat analysis included 133 Asian patients (93 men, 40 women; mean age, 59.5 years), of whom 125 completed 14 weeks of therapy. Their mean blood pressure was 130.2/79.4 mm Hg. Overall, 104 (78.2%) patients treated with simvastatin achieved LDL-C levels ≤100 mg/dL at week 14, and 125 (94.0%) achieved this target at some point during the study. Similarly, 122 (91.7%) patients achieved an LDL-C level ≤115 mg/dL at week 14, and 130 (97.7%) achieved this target at some point during the study. Treatment with simvastatin had favorable effects on the lipid profile, producing significant percentage changes from baseline in all parameters (P < 0.001). Simvastatin was well tolerated across the dose range. Overall, 40 patients (30.1%) had ≥1 clinical adverse experience. Only 14 (10.5%) had adverse experiences that were possibly, probably, or definitely related to study drug; none of these experiences were considered serious. The most common adverse experiences (≥3% incidence) were abdominal pain (6%); chest pain (5%); dizziness (4%); and asthenia/fatigue, fibromyalgia, headache, insomnia, and upper respiratory tract infection (3% each). No new or unexpected adverse experiences were seen at the higher doses. Conclusions: Simvastatin was effective and well tolerated at doses of 20, 40, and 80 mg/d in Asian patients with coronary heart disease. Titration enabled the majority to achieve target LDL-C levels of ≤100 mg/dL.

AB - Background: Most published studies on the use of lipid-lowering agents to treat hyper-cholesterolemia have focused on Western populations, with few data on Asian populations. Objective: The Simvastatin Treats Asians to Target (STATT) study used a titrate-to-goal protocol to evaluate the efficacy and tolerability of simvastatin 20 to 80 mg/d in the treatment of Asian patients with coronary heart disease. Methods: This was a multicenter, open-label, uncontrolled, 14-week study in patients with coronary heart disease and serum low-density lipoprotein cholesterol (LDL-C) levels of 115-180 mg/dL and triglyceride levels of ≤400 mg/dL. The dose of simvastatin was titrated from 20 to 80 mg/d to achieve the National Cholesterol Education Program (NCEP) LDL-C target of ≤100 mg/dL. The primary efficacy measure was the percentage of patients achieving the NCEP target. Among secondary measures were the percentage of patients achieving European Society of Cardiology/European Atherosclerosis Society/European Society of Hypertension target LDL-C levels of ≤115 mg/dL and the percentage change from baseline in lipid parameters. Tolerability was assessed in terms of the overall incidence of adverse experiences and the incidences of the most commonly reported adverse experiences. Results: The intent-to-treat analysis included 133 Asian patients (93 men, 40 women; mean age, 59.5 years), of whom 125 completed 14 weeks of therapy. Their mean blood pressure was 130.2/79.4 mm Hg. Overall, 104 (78.2%) patients treated with simvastatin achieved LDL-C levels ≤100 mg/dL at week 14, and 125 (94.0%) achieved this target at some point during the study. Similarly, 122 (91.7%) patients achieved an LDL-C level ≤115 mg/dL at week 14, and 130 (97.7%) achieved this target at some point during the study. Treatment with simvastatin had favorable effects on the lipid profile, producing significant percentage changes from baseline in all parameters (P < 0.001). Simvastatin was well tolerated across the dose range. Overall, 40 patients (30.1%) had ≥1 clinical adverse experience. Only 14 (10.5%) had adverse experiences that were possibly, probably, or definitely related to study drug; none of these experiences were considered serious. The most common adverse experiences (≥3% incidence) were abdominal pain (6%); chest pain (5%); dizziness (4%); and asthenia/fatigue, fibromyalgia, headache, insomnia, and upper respiratory tract infection (3% each). No new or unexpected adverse experiences were seen at the higher doses. Conclusions: Simvastatin was effective and well tolerated at doses of 20, 40, and 80 mg/d in Asian patients with coronary heart disease. Titration enabled the majority to achieve target LDL-C levels of ≤100 mg/dL.

UR - http://www.scopus.com/inward/record.url?scp=0034985133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034985133&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(01)80074-6

DO - 10.1016/S0149-2918(01)80074-6

M3 - Article

VL - 23

SP - 858

EP - 870

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -